STEMCELLS INC Form 8-K October 07, 2010

Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Ear	rliest Event Reported):	October 7, 2010

StemCells, Inc.

(Exact name of registrant as specified in its charter)

000-19871

(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
3155 Porter Drive, Palo Alto, California		94304
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area code:		650.475.3100
	Not Applicable	
Former name or for	rmer address, if changed since	e last report
Check the appropriate box below if the Form 8-K filing is inte the following provisions:	ended to simultaneously satisf	y the filing obligation of the registrant under any of
[] Written communications pursuant to Rule 425 under the S	Securities Act (17 CFR 230.42	25)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

94-3078125

Edgar Filing: STEMCELLS INC - Form 8-K

Top	of	the	e Form	i
Item	8.	01	Other	Events.

On October 7, 2010, StemCells, Inc. reported progress in its Phase I clinical trial in Pelizaeus-Merzbacher Disease. The full text of this press release is attached hereto as Exhibit 99.1.

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

October 7, 2010 By: /s/ Kenneth Stratton

Name: Kenneth Stratton Title: General Counsel

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description	
99.1	Press Release of StemCells, Inc. dated October 7, 2010	